JurongHealth Campus. Source: NTFGH
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Austco Healthcare (AHC) has been awarded a $1.3 million contract to update the nurse call system for the JurongHealth Campus in Singapore
  • The Tacera solution will be integrated with JurongHealth’s Code Blue Platform and will be the fastest code blue rapid response of any Singapore hospital
  • Tacera’s software is the only nurse call solution on the market that has voice over internet protocol (VoIP)
  • On market close, Austco is up 14.1 per cent and is trading at 10.5 cents per share

Austco Healthcare (AHC) has won a $1.3 million contract to update the nurse call system for the JurongHealth Campus in Singapore.

The company will upgrade the Tacera Nurse Call platform that is installed in the 700-bed Ng Teng Fong General Hospital (NTFGH) and the 400-bed Jurong Community Hospital (JCH).

Austco was chosen as Tacera’s software is the only nurse call solution on the market that has voice over internet protocol (VoIP) to the patients’ bedside and provides a foundation for future products and services.

The Tacera solution will be integrated with JurongHealth’s Code Blue Platform. The combined technology will be able to deliver the fastest code blue rapid response of any hospital in Singapore.

NTFGH and JCH were the first hospitals in Singapore to be designed and built together from the ground up as an integrated healthcare development.

“We are aligned with JurongHealth’s mission of advancing healthcare by synergizing technology,” Austco CEO Clayton Astles said.

“At Austco, our focus is on providing innovative solutions, like our exceptional Tacera nurse call system, that delivers quality care and optimises the patient experience,” he added.

On market close, Austco is up 14.1 per cent and is trading at 10.5 cents per share.

AHC by the numbers
More From The Market Online
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…
Immune system concept ai gen

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has…